BioCentury
ARTICLE | Clinical News

Coherus' CHS-1420 similar to Humira in Phase III trial

August 8, 2016 7:00 AM UTC

Coherus BioSciences Inc. (NASDAQ:CHRS) said its biosimilar CHS-1420 met the primary endpoint of similarity to reference product Humira adalimumab from AbbVie Inc. (NYSE:ABBV) based on PASI 75 response rates at week 12 in the Phase III PsOsim study to treat active, moderate to severe chronic plaque psoriasis. Coherus said CHS-1420 and Humira were also "similarly well tolerated" and had similar safety profiles.

Coherus expects 16- and 24-week data next quarter, with a BLA submission to follow. The company intends to present the data at an upcoming scientific conference. ...